CTKB Relative Valuation
CTKB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CTKB is overvalued; if below, it's undervalued.
Historical Valuation
Cytek Biosciences Inc (CTKB) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 82.54. The fair price of Cytek Biosciences Inc (CTKB) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：4.86
Fair
-162.33
PE
1Y
3Y
5Y
Trailing
Forward
95.47
EV/EBITDA
Cytek Biosciences Inc. (CTKB) has a current EV/EBITDA of 95.47. The 5-year average EV/EBITDA is 50.42. The thresholds are as follows: Strongly Undervalued below -28.87, Undervalued between -28.87 and 10.77, Fairly Valued between 90.06 and 10.77, Overvalued between 90.06 and 129.70, and Strongly Overvalued above 129.70. The current Forward EV/EBITDA of 95.47 falls within the Overvalued range.
-11.17
EV/EBIT
Cytek Biosciences Inc. (CTKB) has a current EV/EBIT of -11.17. The 5-year average EV/EBIT is 112.70. The thresholds are as follows: Strongly Undervalued below -535.18, Undervalued between -535.18 and -211.24, Fairly Valued between 436.63 and -211.24, Overvalued between 436.63 and 760.57, and Strongly Overvalued above 760.57. The current Forward EV/EBIT of -11.17 falls within the Historic Trend Line -Fairly Valued range.
3.10
PS
Cytek Biosciences Inc. (CTKB) has a current PS of 3.10. The 5-year average PS is 6.79. The thresholds are as follows: Strongly Undervalued below -3.54, Undervalued between -3.54 and 1.63, Fairly Valued between 11.96 and 1.63, Overvalued between 11.96 and 17.13, and Strongly Overvalued above 17.13. The current Forward PS of 3.10 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Cytek Biosciences Inc. (CTKB) has a current P/OCF of 0.00. The 5-year average P/OCF is -39.95. The thresholds are as follows: Strongly Undervalued below -513.25, Undervalued between -513.25 and -276.60, Fairly Valued between 196.71 and -276.60, Overvalued between 196.71 and 433.36, and Strongly Overvalued above 433.36. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Cytek Biosciences Inc. (CTKB) has a current P/FCF of 0.00. The 5-year average P/FCF is 17.80. The thresholds are as follows: Strongly Undervalued below -42.29, Undervalued between -42.29 and -12.24, Fairly Valued between 47.85 and -12.24, Overvalued between 47.85 and 77.89, and Strongly Overvalued above 77.89. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Cytek Biosciences Inc (CTKB) has a current Price-to-Book (P/B) ratio of 1.64. Compared to its 3-year average P/B ratio of 2.13 , the current P/B ratio is approximately -22.75% higher. Relative to its 5-year average P/B ratio of -0.17, the current P/B ratio is about -1060.16% higher. Cytek Biosciences Inc (CTKB) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 0.73%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 0.44% , the current FCF yield is about -100.00% lower.
1.64
P/B
Median3y
2.13
Median5y
-0.17
-0.93
FCF Yield
Median3y
0.73
Median5y
0.44
Competitors Valuation Multiple
The average P/S ratio for CTKB's competitors is , providing a benchmark for relative valuation. Cytek Biosciences Inc Corp (CTKB) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 1.54%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CTKB decreased by 25.12% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -6.07 to -45.28.
The secondary factor is the Revenue Growth, contributed 1.54%to the performance.
Overall, the performance of CTKB in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Cytek Biosciences Inc (CTKB) currently overvalued or undervalued?
What is Cytek Biosciences Inc (CTKB) fair value?
How does CTKB's valuation metrics compare to the industry average?
What is the current P/B ratio for Cytek Biosciences Inc (CTKB) as of Dec 13 2025?
What is the current FCF Yield for Cytek Biosciences Inc (CTKB) as of Dec 13 2025?
What is the current Forward P/E ratio for Cytek Biosciences Inc (CTKB) as of Dec 13 2025?